P Caruana1, K Lemmert2, K Ribbons3, R Lea4, J Lechner-Scott1. 1. Department of Neurology, John Hunter Hospital, New Lambton, NSW, Australia; Hunter Medical Research Institute, New Lambton, NSW, Australia. 2. Pathology North, New Lambton, NSW, Australia. 3. Department of Neurology, John Hunter Hospital, New Lambton, NSW, Australia. 4. Hunter Medical Research Institute, New Lambton, NSW, Australia.
Abstract
BACKGROUND: The importance of the innate immune system in multiple sclerosis (MS) is increasingly recognized and the role of natural killer (NK) cells in controlling autoimmunity may be an important modulator of disease activity. OBJECTIVE: To examine NK subsets in MS patients on different treatments and to evaluate the role of NK subsets as indicators for disease activity. METHODS: We measured NK subset levels in blood obtained from 110 relapsing-remitting MS patients. Patients were either off treatment or on treatment with natalizumab, fingolimod, glatiramer acetate or beta-interferon. Disease activity was defined according to 'No Evidence of Disease Activity' (NEDA) criteria within an observation period of up to 2.4 years. The mean NK subset levels were compared among treatment groups using multivariate analysis of variance (ANOVA) and association analysis with disease activity performed using multi-factor logistic regression. RESULTS: Our analysis revealed differences in NK cells and subsets on treatment compared to off treatment ( p < 0.0005). A high proportion of bright NK cells were significantly associated with stable magnetic resonance imaging (MRI) imaging after adjusting for treatment effects ( p < 0.05). CONCLUSION: The independent association of NK subsets with MRI stability needs to be confirmed in prospective studies to test their usefulness in predicting disease activity in MS patients.
BACKGROUND: The importance of the innate immune system in multiple sclerosis (MS) is increasingly recognized and the role of natural killer (NK) cells in controlling autoimmunity may be an important modulator of disease activity. OBJECTIVE: To examine NK subsets in MSpatients on different treatments and to evaluate the role of NK subsets as indicators for disease activity. METHODS: We measured NK subset levels in blood obtained from 110 relapsing-remitting MSpatients. Patients were either off treatment or on treatment with natalizumab, fingolimod, glatiramer acetate or beta-interferon. Disease activity was defined according to 'No Evidence of Disease Activity' (NEDA) criteria within an observation period of up to 2.4 years. The mean NK subset levels were compared among treatment groups using multivariate analysis of variance (ANOVA) and association analysis with disease activity performed using multi-factor logistic regression. RESULTS: Our analysis revealed differences in NK cells and subsets on treatment compared to off treatment ( p < 0.0005). A high proportion of bright NK cells were significantly associated with stable magnetic resonance imaging (MRI) imaging after adjusting for treatment effects ( p < 0.05). CONCLUSION: The independent association of NK subsets with MRI stability needs to be confirmed in prospective studies to test their usefulness in predicting disease activity in MSpatients.
Authors: Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger Journal: Nat Rev Immunol Date: 2022-05-04 Impact factor: 53.106
Authors: Stephanie Trend; Anderson P Jones; Sian Geldenhuys; Scott N Byrne; Marzena J Fabis-Pedrini; David Nolan; David R Booth; William M Carroll; Robyn M Lucas; Allan G Kermode; Prue H Hart Journal: Int J Mol Sci Date: 2017-06-15 Impact factor: 5.923
Authors: Peter J Darlington; Brandon Stopnicki; Tarik Touil; Jean-Sebastien Doucet; Lama Fawaz; Morgan E Roberts; Marie-Noëlle Boivin; Nathalie Arbour; Mark S Freedman; Harold L Atkins; Amit Bar-Or Journal: Front Immunol Date: 2018-05-07 Impact factor: 7.561
Authors: Thanmayi Ranganath; Laura J Simpson; Anne-Maud Ferreira; Christof Seiler; Elena Vendrame; Nancy Zhao; Jason D Fontenot; Susan Holmes; Catherine A Blish Journal: Front Immunol Date: 2020-04-24 Impact factor: 7.561